ROCHE REMAINS A BELLWETHER, DESPITE RECENT (R&D) JITTERS (ADD; 14% UPSIDE)
19/09/22 -" Since early 2022, an already fragile global economy (surfing on monetary excesses) has faced several challenges – spiralling inflation and supply-chain disruptions – due to the war in Europe, ..."
Pages
66
Language
English
Published on
19/09/22
You may also be interested by these reports :
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...
30/12/25
Over the last three years, GSK’s earnings have exceeded the market’s expectations on most occasions. Moreover, the firm’s R&D efforts have yielded ...
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...